Friedrich Graf Finckenstein - 02 Sep 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Medical Officer
Signature
/s/ Friedrich Graf Finckenstein
Issuer symbol
IOVA
Transactions as of
02 Sep 2025
Net transactions value
-$14,121
Form type
4
Filing time
04 Sep 2025, 18:30:29 UTC
Previous filing
04 Jun 2025
Next filing
03 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS /s/ Friedrich Graf Finckenstein 04 Sep 2025 0001782981

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +12,697 +13% $0.000000 111,857 02 Sep 2025 Direct F1
transaction IOVA Common Stock Tax liability $14,121 -6,448 -5.8% $2.19 105,409 02 Sep 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -3,907 -33% $0.000000 7,813 02 Sep 2025 Common stock 3,907 Direct F4, F5, F6
transaction IOVA Restricted Stock Units Options Exercise $0 -8,790 -14% $0.000000 52,738 02 Sep 2025 Common stock 8,790 Direct F4, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3 Represents the common stock remaining after deducting the common stock withheld for taxes.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5 The remaining RSUs will vest in equal quarterly installments.
F6 Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
F7 Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.